Skip to content

Study on the Safety and Efficacy of Bupivacaine Liposomal Injection TAP Block for Laparoscopic Colorectal Cancer Surgical Analgesia

Study on the Safety and Efficacy of Bupivacaine Liposomal Injection TAP Block for Laparoscopic Colorectal Cancer Surgical Analgesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083108
Enrollment
Unknown
Registered
2024-04-16
Start date
2024-04-16
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Bupivacaine liposomal group:Bupivacaine liposomal group (group B): performed bilaterally with 40 ml of ED95 bupivacaine liposome in patients under ultrasound guidance prior to anesthesia induction
Ropivacaine group:Ropivacaine group (R group): performed bilaterally with 40ml of 0.4% ropivacaine under ultrasound guidance before anesthesia induction

Sponsors

Tianjin People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) I have a clear understanding and voluntarily participate in the study, and I have signed an informed consent form; (2) Planned to undergo elective laparoscopic colorectal cancer resection surgery; (3) ASA level I to III; (4) Clear consciousness, no cognitive impairment or other mental illnesses; (5) Stable condition, able to cooperate in completing research.

Exclusion criteria

Exclusion criteria: 1)BMI 30 kg/m2; 2)Injection site infection; 3)Have taken a long-acting opioid within 3 days or any opioid within 24 hours before surgery; 4)Existing coagulopathy; 5)Recent history of drug or alcohol abuse; 6)Known allergy to one of the study drugs; 7) Patients with acute and critical illnesses (including acute heart failure, acute stroke, acute myocardial infarction, severe infection, etc.); 8)Psychiatric or cognitive impairment that may interfere with perioperative assessment.

Design outcomes

Primary

MeasureTime frame
Accumulated consumption of opioids at 1, 2, 4, 6, 8, 12, 36, and 48 hours after surgery;VAS score at rest and exercise (deep cough, supine position 90 °, etc.) time points;First time using PCA;Patient satisfaction with pain management;Total use of anesthesia and vasoactive drugs during surgery;Intraoperative hemodynamic conditions;First postoperative analgesia time;Postoperative 8hNRS score;

Secondary

MeasureTime frame
First exhaust time;Getting out of bed activities and discharge time;Perioperative adverse reactions (nausea, vomiting, fever, itching, constipation, etc.);Incidence of postoperative hemodynamic instability;Patient satisfaction with postoperative pain control was recorded;

Countries

China

Contacts

Public ContactShuhua Xie

Tianjin People's Hospital, No. 190 Jieyuan Road, Hongqiao District, Tianjin

xieshuhua001@123.com+86 150 2268 9349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026